Initiating insulin glargine 300 U/mL could help half of those patients whose type 2 diabetes is inadequately controlled with oral antidiabetic medication to achieve their personal glycemic target within a year, real-world data suggest.
People with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors are less likely to develop gout than those given glucagon-like peptide-1 receptor agonists, researchers report.
Continuous subcutaneous insulin infusion users have more stable glycated hemoglobin levels over the long term than multiple daily injection users with type 1 diabetes, a real-world study suggests.
Patients with type 2 diabetes who are treated with SGLT2 inhibitors in routine clinical practice have a lower rate of kidney function decline and a reduced risk for adverse renal events compared with those given other glucose-lowering drugs, researchers report.
Adding the DPP-4 inhibitor sitagliptin to first-line metformin therapy may delay the need for exogenous insulin among people with type 2 diabetes, researchers report.
Fasting C-peptide levels can “provide valuable information” to guide the approach to titrating basal insulin in new users with type 2 diabetes, say researchers.
Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.
Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity [read more].
Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.
The risk for severe urinary tract infections among people with type 2 diabetes in the real-world setting may be no greater with use of sodium-glucose cotransporter 2 inhibitors than with other modern antidiabetes medications, research suggests.
Nurse and Diabetes Educator Lori Berard highlights the advantages of “concentrated” insulins and outlines her recommendations for getting titration right for patients.
WATCH | Katherine Tuttle and Jay Shubrook reconvene to discuss what the landmark findings from recent renal outcomes trials mean for clinical practice (16:51).
Our clinical advisors discuss their EASD 2019 highlights, including new treatment options for children and older adults with type 2 diabetes, the complexities surrounding hypoglycemia prevention, and the implications of the VERIFY trial.
An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
